Teva Strikes Two Major Deals For Eculizumab And Aflibercept Biosimilars
Samsung And Formycon Supply US Soliris And European Eylea Rivals
Teva has announced two major biosimilars deals in quick succession, partnering with Samsung Bioepis on its US Epysqli eculizumab rival to Soliris and Formycon on its European Ahzantive aflibercept challenger to Eylea.
